SZEY-2108 / Erye Pharma - LARVOL DELTA

Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts (clinicaltrials.gov) - P1 | N=64 | Terminated | Sponsor: Suzhou Erye Pharmaceutical Co., Ltd. | Trial completion date: Oct 2024 ➔ May 2024 | Recruiting ➔ Terminated; Due to the termination criteria for dose escalation in the clinical protocol having been reached, this trial is terminated.

Trial completion date • Trial termination • Infectious Disease

Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts (clinicaltrials.gov) - P1 | N=82 | Recruiting | Sponsor: Suzhou Erye Pharmaceutical Co., Ltd.

New P1 trial • Infectious Disease